IPM IMPACT
IPM IMPACT has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €43k and a net result of €10k. Equity is growing by ~7.4% per year across the filed fiscal years. Its solvency ranks better than 21% of 509 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
| Equity | €43k |
| Net result | €10k |
| Staff (FTE) | 1.7 |
| Better than sector | 21% |
Strong profile, led by profitability.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 13.6% | 61.7% | |
| Net result | €10k | €29k | |
| Equity | €43k | €122k | |
| Gross operating margin | €158k | €67k | |
| Staff costs | €115k | €44k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | €0 | €0 | €0 | €0 | €0 |
| EBITDA | €40k | €29k | €42k | €-25k | €34k |
| Net profit | €10k | €5k | €13k | €-56k | €56k |
| Cash flow | €33k | €28k | €35k | €-32k | €79k |
| Staff costs | €115k | €172k | €210k | €203k | - |
| Income taxes | €783 | €443 | €456 | €455 | €360 |
| Dividends | - | - | - | - | - |
| Total assets | €315k | €364k | €376k | €306k | €370k |
| Equity | €43k | €33k | €33k | €24k | €84k |
| Debt | €272k | €331k | €344k | €282k | €285k |
| of which ≤ 1y | €253k | €293k | €322k | €243k | €229k |
| of which > 1y | €17k | €35k | €20k | €36k | €56k |
| Working capital | €-16k | €-31k | €-27k | €-30k | €42k |
| Employees (FTE) | 1.7 | 2.6 | 3.0 | 3.1 | 3.0 |
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 0.94 | 0.90 | 0.91 | 0.87 | 1.18 |
| Quick ratio | 0.94 | 0.90 | 0.91 | 0.87 | 1.18 |
| Working capital ratio | -5.1% | -8.4% | -7.3% | -10.0% | 11.4% |
| Solvency | 13.6% | 9.0% | 8.6% | 7.9% | 22.8% |
| Debt / equity | 6.33 | 10.13 | 10.57 | 11.69 | 0.67 |
| Long-term debt ratio | 0.39 | 1.07 | 0.60 | 1.50 | 0.67 |
| Interest coverage | 5.75 | 4.64 | 3.81 | -2.23 | - |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 3.3% | 1.3% | 3.5% | -18.2% | 15.2% |
| ROE | 24.0% | 14.6% | 40.2% | -230.8% | 66.6% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Full annual accounts (26 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €315k | €364k | €376k | €306k | €370k |
| Fixed assets | 21/28 | €79k | €101k | €82k | €93k | €99k |
| Intangible fixed assets | 21 | €5k | €10k | €19k | €20k | €28k |
| Tangible fixed assets | 22/27 | €71k | €89k | €61k | €71k | €68k |
| Financial fixed assets | 28 | €2k | €2k | €2k | €2k | €2k |
| Current assets | 29/58 | €237k | €263k | €294k | €212k | €271k |
| Amounts receivable within one year | 40/41 | €232k | €257k | €283k | €197k | €266k |
| Cash & bank | 54/58 | €0 | €2k | €8k | €10k | €4k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €315k | €364k | €376k | €306k | €370k |
| Equity | 10/15 | €43k | €33k | €33k | €24k | €84k |
| Contributions / capital | 10/11 | €12k | €12k | €12k | €12k | - |
| Reserves | 13 | €2k | €2k | €2k | €2k | €2k |
| Accumulated profits (losses) | 14 | €29k | €18k | €14k | €540 | €56k |
| Amounts payable | 17/49 | €272k | €331k | €344k | €282k | €285k |
| Amounts payable after one year | 17 | €17k | €35k | €20k | €36k | €56k |
| Amounts payable within one year | 42/48 | €253k | €293k | €322k | €243k | €229k |
| Trade debts payable within one year | 44 | €71k | €92k | €108k | €49k | €68k |
| Income statement | ||||||
| Turnover | 70 | €0 | €0 | €0 | €0 | €0 |
| Gross operating margin | 9900 | €158k | €216k | €255k | €181k | €226k |
| Operating result | 9901 | €18k | €6k | €20k | €-49k | €12k |
| Financial income | 75 | - | €5k | €5k | €5k | €5k |
| Financial charges | 65 | €7k | €6k | €11k | €11k | €11k |
| Result before taxes | 9903 | €11k | €5k | €14k | €-55k | €5k |
| Income taxes | 67/77 | €783 | €443 | €456 | €455 | €360 |
| Net result for the period | 9904 | €10k | €5k | €13k | €-56k | €5k |
| Result to be appropriated | 9905 | €10k | €5k | €13k | €-56k | €5k |
| NACE primary | Research and development on biotechnology(72101) |
| Legal form | Private limited company(610) |
| Incorporation | 12-05-2010 |
| Status | Active |
| Postal code | 3511 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 72026A1356/00N000 | Flanders | 1.0 ha | 1 · 1,790 m² | 0.0 m |
| 71032A0118/00D007 | Flanders | 382 m² | 1 · 123 m² | 7.4 m · 2 fl. |
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
02-01-2024 Discharge granted to the board
Technical details
{
"events": [
{
"kind": "decharge_pending",
"role": null,
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De algemene vergadering zal op de volgende jaarvergadering beslissen over de kwijting aan de ontslagnemende zaakvoerder voor de uitoefening van hun mandaat.",
"decharge_status": "pending_next_agm",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "decharge_granted",
"role": null,
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "De algemene vergadering zal op de volgende jaarvergadering beslissen over de kwijting aan de ontslagnemende zaakvoerder voor de uitoefening van hun mandaat.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Frederik Van Damme",
"firm_city": null,
"firm_name": null,
"office_city": "Hasselt",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-01-02",
"filing_date": "2023-12-28",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2023-12-20",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0825.883.734",
"name_full": "IPM IMPACT",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Frederik Van Damme",
"org_rep_person_name": null,
"person_role_at_subject": "notaris"
},
"co_filed_documents": [
"uitgifte van akte",
"geco\u00F6rdineerde statuten",
"verslag bestuursorgaan"
],
"corrected_publication_numac": null
}| Legal nameNL | IPM IMPACT |